PL447254A1 - Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych - Google Patents

Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych

Info

Publication number
PL447254A1
PL447254A1 PL447254A PL44725423A PL447254A1 PL 447254 A1 PL447254 A1 PL 447254A1 PL 447254 A PL447254 A PL 447254A PL 44725423 A PL44725423 A PL 44725423A PL 447254 A1 PL447254 A1 PL 447254A1
Authority
PL
Poland
Prior art keywords
treatment
phenylpiperazinamide
neurological diseases
amino acid
acid fragments
Prior art date
Application number
PL447254A
Other languages
English (en)
Inventor
Krzysztof KAMIŃSKI
Marcin JAKUBIEC
Michał ABRAM
Rafał KAMIŃSKI
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Priority to PL447254A priority Critical patent/PL447254A1/pl
Priority to PCT/PL2024/050103 priority patent/WO2025136133A1/en
Publication of PL447254A1 publication Critical patent/PL447254A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

W zgłoszeniu ujawniono grupę związków chemicznych, zwłaszcza do leczenia chorób neurologicznych, będących fenylopiperazynamidami modyfikowanymi fragmentami niearomatycznych aminokwasów.
PL447254A 2023-12-22 2023-12-22 Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych PL447254A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL447254A PL447254A1 (pl) 2023-12-22 2023-12-22 Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych
PCT/PL2024/050103 WO2025136133A1 (en) 2023-12-22 2024-12-19 Phenylpiperazinamide derivatives modified with aliphatic amino acid fragments for the treatment of neurological diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL447254A PL447254A1 (pl) 2023-12-22 2023-12-22 Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych

Publications (1)

Publication Number Publication Date
PL447254A1 true PL447254A1 (pl) 2025-06-23

Family

ID=94824095

Family Applications (1)

Application Number Title Priority Date Filing Date
PL447254A PL447254A1 (pl) 2023-12-22 2023-12-22 Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych

Country Status (2)

Country Link
PL (1) PL447254A1 (pl)
WO (1) WO2025136133A1 (pl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL428485A1 (pl) * 2019-01-07 2020-07-13 Uniwersytet Jagielloński Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL428485A1 (pl) * 2019-01-07 2020-07-13 Uniwersytet Jagielloński Pochodne (2,5-dioksopirolidyn-1-ylo)(fenylo)-acetamidu i ich zastosowanie do leczenia chorób o podłożu neurologicznym

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KRZYSZTOF KAMIŃSKI ET AL.: "Epilepsia 2020, 61(10), pp. 2119-2128 doi: 10.1111/epi.16669", "KA-104, A NEW MULTITARGETED ANTICONVULSANT WITH POTENT ANTINOCICEPTIVE ACTIVITY IN PRECLINICAL MODELS." *
KRZYSZTOF KAMIŃSKI ET AL.: "Journal of Medicinal Chemistry 2015, 58(13), pp. 5274-5286 doi: 10.1021/acs.jmedchem.5b00578", "DESIGN, SYNTHESIS, AND ANTICONVULSANT ACTIVITY OF NEW HYBRID COMPOUNDS DERIVED FROM 2-(2,5-DIOXOPYRROLIDIN-1-YL)PROPANAMIDES AND 2-(2,5-DIOXOPYRROLIDIN-1-YL)BUTANAMIDES." *
MARCIN JAKUBIEC ET AL.: "Cells 2022, 11(12), 1862 doi: 10.3390/cells11121862", "NEW PHENYLGLYCINAMIDE DERIVATIVES WITH HYBRID STRUCTURE AS CANDIDATES FOR NEW BROAD-SPECTRUM ANTICONVULSANTS." *
MICHAŁ ABRAM ET AL.: "Journal of Medicinal Chemistry 2017, 60(20), pp. 8565–8579 doi: 10.1021/acs.jmedchem.7b01114", "MULTIFUNCTIONAL HYBRID COMPOUNDS DERIVED FROM 2-(2,5-DIOXOPYRROLIDIN-1-YL)-3-METHOXYPROPANAMIDES WITH ANTICONVULSANT AND ANTINOCICEPTIVE PROPERTIES." *

Also Published As

Publication number Publication date
WO2025136133A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
EA202191730A1 (ru) Ингибиторы kif18a
SA521431048B1 (ar) مركبات بيروليدين
MX2021007157A (es) Heteroarilamidas utiles como inhibidores de kif18a.
MX419368B (es) Heteroarilamidas utiles como inhibidores de kif18a
CR20240120A (es) Compuesto inductor de la degradación de PLK1 novedoso
MX2020011845A (es) Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
WO2023078333A8 (zh) 一种取代的苯丙酸衍生物及其用途
NO20082510L (no) En fremgangsmate for konsentrasjon av et polypeptid
BR112021020241A2 (pt) Derivados de heteroarila bicíclica como inibidores de ectonucleotídeo pirofosfatase fosfodiesterase 1
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
BR112021014220A2 (pt) Derivados heterocíclicos
BR112021020295A2 (pt) Agentes antiproliferativos para o tratamento de pah
MX2023014197A (es) Compuestos de azetidinilo que comprenden un grupo de acido carboxilico para el tratamiento de enfermedades neurodegenerativas.
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
JOP20250057A1 (ar) مركبات لعلاج السرطان
PL447254A1 (pl) Pochodne fenylopiperazynamidowe modyfikowane fragmentami alifatycznych aminokwasów do leczenia chorób neurologicznych
MX2024003412A (es) Terapia de regulon de arnm para el tratamiento de los trastornos por haploinsuficiencia.
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina
MX2024010402A (es) Inhibidores de proteinas de union a emopamilo y usos de estos
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
PY2038553A (es) Agroquímicos
MX2021015214A (es) Compuestos para tratar enfermedad respiratoria.
BR112021022270A2 (pt) Materiais e métodos para tratar degeneração macular relacionada à idade
ZA202304030B (en) Modified cxcl10 for immunotherapy of cancer diseases
JOP20220211A1 (ar) تركيبات صيدلانية من أملاح إستر كولين حمض ليبويك وطرق للمعالجة باستخدامها